NCT07328230Recruiting
Superselective Adrenal Arterial Embolization Versus Oral Spironolactone for Treatment of Idiopathic Hyperaldosteronism
A Prospective Randomized Controlled Trial for Treatment of Idiopathic Hyperaldosteronism: Superselective Adrenal Arterial Embolization Versus Oral Spironolactone
Source: ClinicalTrials.gov · Last updated 9 Jan 2026
Brief summary (registry, in English)
Idiopathic hyperaldosteronism (IHA) represents about 65% of primary hyperaldosteronism cases. Although mineralocorticoid receptor antagonists (MRAs) are the standard first-line treatment, they are often limited by adverse effects. Superselective adrenal artery embolization (SAAE) has been utilized for IHA over the last decade, yet comparative studies against MRAs are lacking. The objective of this study is to compare the safety and efficacy of SAAE and MRA to determine the feasibility of SAAE in treating IHA.
- Status (registry)
- Recruiting
- Study type
- Interventional
- Enrollment
- 172 (estimated)
- First submitted
- 26 Dec 2025
- Start date
- 1 Aug 2022
- Primary completion date
- 31 Dec 2025
- Lead sponsor
- Chinese Academy of Medical Sciences, Fuwai Hospital
- Diseases
- High blood pressure
- NCT number
- NCT07328230
What you commit to
- Study type: Interventional
- Planned participants: 172
- From 1 Aug 2022 to the primary completion date, 31 Dec 2025
- 3 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Hemorrhagic or ischemic stroke, endovascular stent implantation and myocardial infarction within the previous 3 months;
Other illness
- Severe contrast agent allergy;
- Patients with other serious organic diseases cannot tolerate SAAE treatment;
- Other forms of secondary hypertension.
Lab values
- Renal insufficiency with an estimated glomerular filtration rate (based on the modification of diet in renal disease criteria) \<45 ml/min/1.73 m², and/or serum creatinine \>176 μmol/L；
Other
- Unilateral adrenal hyperplasia;
- Women who are pregnant or planning to become pregnant;
Who the study is looking for
- Aged from 15 to 60 with no limits in sex;
- Patients are diagnosed with primary aldosteronism according to the criteria of the 2016 Endocrine Society guidelines;
- Sub-typing diagnosis confirmed idiopathic hyperaldosteronism;
- Patients or their legal representatives have to sign written informed consent approved by the ethics committee.
Age in the registry: 15 years to 60 years · Sex: All · Does not accept healthy volunteers
Sites (3)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Fuwai Hospital, National Center for Cardiovascular Disease, Chinese Academy of Medical Sciences and Peking Union Medical College Coordinator of this site? Confirm its status | Beijing | China | Recruiting |
| The First Affiliated Hospital of Chengdu Medical College Coordinator of this site? Confirm its status | Chengdu | China | Recruiting |
| Second Affiliated Hospital of Nanchang University Coordinator of this site? Confirm its status | Nanchang | China | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.